Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Payables (2016 - 2025)

Historic Payables for Abvc Biopharma (ABVC) over the last 14 years, with Q3 2025 value amounting to $4.8 million.

  • Abvc Biopharma's Payables rose 699.79% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year increase of 699.79%. This contributed to the annual value of $4.3 million for FY2024, which is 220.18% down from last year.
  • According to the latest figures from Q3 2025, Abvc Biopharma's Payables is $4.8 million, which was up 699.79% from $5.2 million recorded in Q2 2025.
  • Over the past 5 years, Abvc Biopharma's Payables peaked at $5.2 million during Q2 2025, and registered a low of $852500.0 during Q3 2023.
  • Over the past 5 years, Abvc Biopharma's median Payables value was $1.9 million (recorded in 2022), while the average stood at $2.8 million.
  • As far as peak fluctuations go, Abvc Biopharma's Payables crashed by 5432.02% in 2023, and later skyrocketed by 42628.16% in 2024.
  • Over the past 5 years, Abvc Biopharma's Payables (Quarter) stood at $1.6 million in 2021, then increased by 15.47% to $1.9 million in 2022, then surged by 134.86% to $4.4 million in 2023, then fell by 2.2% to $4.3 million in 2024, then rose by 10.36% to $4.8 million in 2025.
  • Its Payables was $4.8 million in Q3 2025, compared to $5.2 million in Q2 2025 and $4.6 million in Q1 2025.